Experience of the United Arab Emirates in the use of monoclonal antibody drug sotrovimab in high-risk vaccinated and unvaccinated patients with COVID-19: an observational cohort study.
Sumaya AbdalateefNoor Majed Al MeheiriMohamed NassefAhmed A ShorrabObaid Al Rahman HashimiSamah AllamMariam Saif AlnaqbiRami H Al-Rifai'Published in: BMJ open (2023)
Among high-risk sotrovimab-infused COVID-19 patients, there were relatively low incidences of disease progression and hospitalisation. Regardless of vaccination history, monoclonal antibody intervention during the early stages of COVID-19 results in better outcomes.